Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Agios Pharmaceuticals (AGIO) over the last 10 years, with Q4 2025 value amounting to $58.0 million.

  • Agios Pharmaceuticals' Shares Outstanding (Diluted Average) rose 14.29% to $58.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.0 million, marking a year-over-year increase of 14.29%. This contributed to the annual value of $58.0 million for FY2025, which is 14.29% up from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) is $58.0 million, which was up 14.29% from $58.1 million recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $69.5 million during Q1 2021, and registered a low of $54.6 million during Q1 2022.
  • For the 5-year period, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $58.0 million, with its median value being $57.1 million (2024).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Diluted Average) plummeted by 2155.2% in 2022, and later soared by 471.14% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $60.4 million in 2021, then decreased by 9.36% to $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then rose by 4.02% to $57.9 million in 2024, then increased by 0.14% to $58.0 million in 2025.
  • Its last three reported values are $58.0 million in Q4 2025, $58.1 million for Q3 2025, and $57.9 million during Q2 2025.